| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 26.05.
| Sanofi, Regeneron Publish Results For Lipid-Lowering PCSK9 Antibody In Lancet | | 203 | AFX News |
| PARIS (dpa-AFX) - Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN)
announced additional positive results from a Phase 2 trial of SAR236553/REGN727
(Study 1003, NTC01266876) in patients...
Mehr lesen zu:
Sanofi, Regeneron Publish Results For Lipid-Lowering PCSK9 Antibody In Lancet | |
| 26.05.
| Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet | | 156 | PR Newswire |
| PARIS and TARRYTOWN, New York, May 26, 2012 /PRNewswire/ --
Global Phase 3 program of SAR236553/REGN727 to be initiated in June across multiple patient populations
Sanofi (EURONEXT: SAN and NYSE:...
Mehr lesen zu:
Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet | |
| 26.05.
| Dubai Health Authority and Sanofi continue momentum to fight diabetes | | 1 | AME Info |
| 25.05.
| Amylin Shares Jump as Sanofi, Merck Sumbit Bids | | 7 | Benzinga.com |
| 25.05.
| Reports: Sanofi, Merck Bid At Least $25 Per Share For Amylin | | 8 | Barron's |
| 25.05.
| Amylin Said to Draw First-Round Bids From Sanofi, Merck | | 5 | Bloomberg |
| 24.05.
| TEXT-S&P summary: Sanofi | | 21 | Reuters.com |
| 23.05.
| BRIEF-Moody's changes outlook on Sanofi's A2 rating to positive from stable | | 16 | Reuters.com |
| 22.05.
| The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr. Reddy's Laboratories | | 76 | PR Newswire |
| CHICAGO, May 22, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr. Reddy's Laboratories | |
| 21.05.
| Sanofi: Kiss This Stock Goodbye | | 68 | Seeking Alpha |
| 18.05.
| Morgan Stanley hebt Ziel für Sanofi auf 70 Euro - 'Overweight' | | 205 | APA-dpa-AFX-Analyser |
| Morgan Stanley hat das Kursziel für
Sanofi von 65,00 auf 70,00 Euro angehoben und die Einstufung auf
"Overweight" belassen. Eine Umfrage unter Ärzten mit
Diabetes-Patienten stütze seine über den...
Mehr lesen zu:
Morgan Stanley hebt Ziel für Sanofi auf 70 Euro - 'Overweight' | |
| 18.05.
| Sanofi: Nachahmer rütteln am Thron: Der Blutverdünner Plavix aus dem Hause Sanofi ... | | 45 | ARD Börse |
| 18.05.
| FDA lässt Sanofi-Generika zu | | 76 | BörseGo |
| Silver Spring (BoerseGo.de) - Der französische Pharmakonzern Sanofi muss generische Konkurrenzprodukte für seinen Verkaufsschlager Plavix akzeptieren. Wie die US-Gesundheitsbehörde FDA am Donnerstag...
Mehr lesen zu:
FDA lässt Sanofi-Generika zu | |
| 17.05.
| FDA genehmigt Generika-Versionen von Sanofi-Blutverdünner Plavix | | 137 | dpa-AFX |
| Die US-amerikanische
Gesundheitsbehörde FDA hat Nachahmer-Versionen des Blutverdünners
Plavix von Sanofi genehmigt. Zu den Herstellern
von Generika des Medikaments, welches das Risiko von Herz-Anfällen
und...
Mehr lesen zu:
FDA genehmigt Generika-Versionen von Sanofi-Blutverdünner Plavix | |
| 17.05.
| Mylan (MYL) Unit Launches Generic Version of Sanofi-Aventis' (SNY) Plavix | | 6 | StreetInsider.com |
| 17.05.
| While U.S. Patients Report High Levels of Satisfaction with Current DMAs, Switching Interest is Highest among Patients for Sanofi / Genzyme's Teriflunomide and Biogen Idec's BG-12, According to a Recent BioTrends Report | | 35 | Business Wire |
| BioTrends Research Group, one of the world's leading research and
advisory firms for specialized biopharmaceutical issues, finds that
patients diagnosed with multiple...
Mehr lesen zu:
While U.S. Patients Report High Levels of Satisfaction with Current DMAs, Switching Interest is Highest among Patients for Sanofi / Genzyme's Teriflunomide and Biogen Idec's BG-12, According to a Recent BioTrends Report | |
| 16.05.
| Sanofi-Aventis Trading Lower Today on Above-Average Volume | | 2 | SmarTrend |
| 16.05.
| Aventis Pharma renamed as Sanofi India | | 6 | moneycontrol.com |
| 15.05.
| AgaMatrix and Sanofi Announce First Glucose Meter to Directly Connect to the iPhone® and iPod® touch | | 46 | PR Newswire |
| SALEM, N.H., May 15, 2012 /PRNewswire/ --AgaMatrix announced today the commercial availability of the iBGStar® Blood Glucose Monitoring System in the U.S., which consists of the iBGStar® blood glucose...
Mehr lesen zu:
AgaMatrix and Sanofi Announce First Glucose Meter to Directly Connect to the iPhone® and iPod® touch | |
| 15.05.
| Sanofi verlängert Mietvertrag vorzeitig | | 77 | Rohmert-Medien |
